Adagio Medical Holdings Inc (ADGM) Stock Price | Live Quotes & Charts | NASDAQ

Adagio Medical Holdings, Inc. (ADGM) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2622801d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Adagio Medical Reports Second Quarter 2026 Results LAGUNA HILLS, CA, August 11, 2026 – Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for th

Adagio Medical (ADGM) shares rose 21.6% Monday and jumped 22% after hours, after the company said its next-generation vCLAS Ultra ULTA system treated its first patient at the University of Pennsylvania. Adagio also said the FDA approved expanding its FULCRUM-VT IDE trial for the new system and expects first-generation ULTA FDA approval soon.

Adagio Medical Holdings (ADGM) said it treated its first patient with its next-generation vCLAS Ultra ultra-low temperature ablation system under FDA expanded access. The patient with non-ischemic cardiomyopathy and prior failed VT ablations was treated at the University of Pennsylvania. Adagio also noted IDE approval for its FULCRUM-VT trial and reported no VT recurrence two months later.

Adagio Medical Holdings (Nasdaq: ADGM) said the FDA granted Expanded Access authorization for its next-generation vCLAS Ultra ULTA system, and clinicians at the Hospital of the University of Pennsylvania treated the first patient with ventricular tachycardia after prior failed ablations. The company expects IDE expansion of its FULCRUM-VT trial to assess the system for sustained monomorphic VT.

Adagio Medical Holdings Inc. said it treated the first patient with its next-generation vCLAS Ultra low-temperature ablation system. The company claims it can reach -170°C and cut ablation time by 50% to 75%, shortening procedures by up to 30 minutes versus the prior system. Adagio noted the FDA granted IDE approval in April to expand its FULCRUM-VT trial. Shares rose 19% to 45 cents.

Adagio Medical Holdings submitted a premarket approval (PMA) application to the FDA for its vCLAS Ventricular Ablation System to treat ventricular tachycardia. The filing is supported by six-month Fulcrum-VT IDE trial data: 84% avoided device shocks and 59% had no VT recurrence. Adagio said the system has CE Mark approval; shares trade near $0.75.